159 related articles for article (PubMed ID: 24583613)
1. Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.
Longosz AF; Morrison CS; Chen PL; Arts E; Nankya I; Salata RA; Franco V; Quinn TC; Eshleman SH; Laeyendecker O
J Acquir Immune Defic Syndr; 2014 Apr; 65(4):390-6. PubMed ID: 24583613
[TBL] [Abstract][Full Text] [Related]
2. Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.
Longosz AF; Serwadda D; Nalugoda F; Kigozi G; Franco V; Gray RH; Quinn TC; Eshleman SH; Laeyendecker O
AIDS Res Hum Retroviruses; 2014 Apr; 30(4):339-44. PubMed ID: 24083837
[TBL] [Abstract][Full Text] [Related]
3. Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort.
Hauser A; Santos-Hoevener C; Meixenberger K; Zimmermann R; Somogyi S; Fiedler S; Hofmann A; Bartmeyer B; Jansen K; Hamouda O; Bannert N; Kuecherer C
PLoS One; 2014; 9(6):e98038. PubMed ID: 24892795
[TBL] [Abstract][Full Text] [Related]
4. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.
Wendel SK; Mullis CE; Eshleman SH; Blankson JN; Moore RD; Keruly JC; Brookmeyer R; Quinn TC; Laeyendecker O
PLoS One; 2013; 8(2):e55525. PubMed ID: 23437058
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D.
Longosz AF; Morrison CS; Chen PL; Brand HH; Arts E; Nankya I; Salata RA; Quinn TC; Eshleman SH; Laeyendecker O
AIDS Res Hum Retroviruses; 2015 Apr; 31(4):421-7. PubMed ID: 25317854
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assay.
Laeyendecker O; Church JD; Oliver AE; Mwatha A; Owen SM; Donnell D; Brookmeyer R; Musoke P; Jackson JB; Guay L; Nakabiito C; Quinn TC; Eshleman SH
PLoS One; 2010 Oct; 5(10):e13259. PubMed ID: 20949006
[TBL] [Abstract][Full Text] [Related]
7. Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda.
Mullis CE; Munshaw S; Grabowski MK; Eshleman SH; Serwadda D; Brookmeyer R; Nalugoda F; Kigozi G; Kagaayi J; Tobian AA; Wawer M; Gray RH; Quinn TC; Laeyendecker O
AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1146-50. PubMed ID: 23641870
[TBL] [Abstract][Full Text] [Related]
8. Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.
Laeyendecker O; Redd AD; Nason M; Longosz AF; Karim QA; Naranbhai V; Garrett N; Eshleman SH; Abdool Karim SS; Quinn TC
J Infect Dis; 2015 Sep; 212(5):754-9. PubMed ID: 25712973
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Performance of Three Biomarker Assays for Recent HIV Infection Using a Well-Characterized HIV-1 Subtype C Incidence Cohort.
Gonese E; Kilmarx PH; van Schalkwyk C; Grebe E; Mutasa K; Ntozini R; Parekh B; Dobbs T; Duong Pottinger Y; Masciotra S; Owen M; Nachega JB; van Zyl G; Hargrove JW
AIDS Res Hum Retroviruses; 2019 Jul; 35(7):615-627. PubMed ID: 30938164
[TBL] [Abstract][Full Text] [Related]
10. Comparison among the BED capture enzyme immunoassay test and AxSYM avidity index assay for determining recent HIV infection and incidence in two Voluntary Counselling and Testing Centres in Northeast Brazil.
Salustiano DM; Lima KO; Cavalcanti AM; Diaz RS; Lacerda HR
Braz J Infect Dis; 2014; 18(4):449-53. PubMed ID: 24780363
[TBL] [Abstract][Full Text] [Related]
11. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.
Laeyendecker O; Brookmeyer R; Mullis CE; Donnell D; Lingappa J; Celum C; Baeten JM; Campbell MS; Essex M; de Bruyn G; Farquhar C; Quinn TC; Eshleman SH;
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1177-83. PubMed ID: 22283149
[TBL] [Abstract][Full Text] [Related]
12. Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity.
Suligoi B; Buttò S; Galli C; Bernasconi D; Salata RA; Tavoschi L; Chiappi M; Mugyenyi P; Pimpinelli F; Kityo C; Regine V; Rezza G
J Clin Virol; 2008 Apr; 41(4):288-92. PubMed ID: 18248848
[TBL] [Abstract][Full Text] [Related]
13. Antibody maturation and viral diversification in HIV-infected women.
James MM; Laeyendecker O; Sun J; Hoover DR; Mullis CE; Cousins MM; Coates T; Moore RD; Kelen GD; Fowler MG; Kumwenda JJ; Mofenson LM; Kumwenda NI; Taha TE; Eshleman SH
PLoS One; 2013; 8(2):e57350. PubMed ID: 23460842
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an antibody avidity index method for detecting recent human immunodeficiency virus type 1 infection using an automated chemiluminescence immunoassay.
Fernández G; Manzardo C; Montoliu A; Campbell C; Fernández G; Casabona J; Miró JM; Matas L; Rivaya B; González V
Enferm Infecc Microbiol Clin; 2015 Apr; 33(4):238-42. PubMed ID: 25060663
[TBL] [Abstract][Full Text] [Related]
15. Performance of a Modified In-House HIV-1 Avidity Assay among a Cohort of Newly Diagnosed HIV-1 Infected Individuals and the Effect of ART on the Maturation of HIV-1 Specific Antibodies.
Alex D; Raj Williams TI; Sachithanandham J; Prasannakumar S; Demosthenes JP; Ramalingam VV; Victor PJ; Rupali P; Fletcher GJ; Kannangai R
Curr HIV Res; 2019; 17(2):134-145. PubMed ID: 31309891
[TBL] [Abstract][Full Text] [Related]
16. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies.
Duong YT; Qiu M; De AK; Jackson K; Dobbs T; Kim AA; Nkengasong JN; Parekh BS
PLoS One; 2012; 7(3):e33328. PubMed ID: 22479384
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes.
Chawla A; Murphy G; Donnelly C; Booth CL; Johnson M; Parry JV; Phillips A; Geretti AM
J Clin Microbiol; 2007 Feb; 45(2):415-20. PubMed ID: 17151211
[TBL] [Abstract][Full Text] [Related]
18. Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.
Kirkpatrick AR; Patel EU; Celum CL; Moore RD; Blankson JN; Mehta SH; Kirk GD; Margolick JB; Quinn TC; Eshleman SH; Laeyendecker O
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):756-62. PubMed ID: 26988426
[TBL] [Abstract][Full Text] [Related]
19. Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.
Konikoff J; Brookmeyer R; Longosz AF; Cousins MM; Celum C; Buchbinder SP; Seage GR; Kirk GD; Moore RD; Mehta SH; Margolick JB; Brown J; Mayer KH; Koblin BA; Justman JE; Hodder SL; Quinn TC; Eshleman SH; Laeyendecker O
PLoS One; 2013; 8(12):e82772. PubMed ID: 24386116
[TBL] [Abstract][Full Text] [Related]
20. Short Communication: Low False Recent Rate of Limiting-Antigen Avidity Assay Among Long-Term Infected Subjects from Guangxi, China.
Yu L; Laeyendecker O; Wendel SK; Liang F; Liu W; Wang X; Wang L; Pang X; Fang Z
AIDS Res Hum Retroviruses; 2015 Dec; 31(12):1247-9. PubMed ID: 26331573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
